ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
Authors
Keywords
-
Journal
Pharmacology Research & Perspectives
Volume 8, Issue 4, Pages -
Publisher
Wiley
Online
2020-08-13
DOI
10.1002/prp2.565
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Development of Bruton’s tyrosine kinase Inhibitors for Rheumatoid Arthritis
- (2018) Lv Jiahui et al. CURRENT MEDICINAL CHEMISTRY
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- An Efficient and Scalable Synthesis of tert-Butyl (3aR,6aS)-5-Oxohexahydrocyclo penta[c]pyrrole-2(1H)-carboxylate: A Pharmacologically Important Intermediate
- (2017) Rajesh H. Bahekar et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
- (2017) Kathleen M. Gillooly et al. PLoS One
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
- (2017) Alexander N. R. Weber et al. Frontiers in Immunology
- Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling
- (2016) L de Zwart et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma
- (2016) Scott A. Ezell et al. Oncotarget
- Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function
- (2015) Li Ren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prolonged and tunable residence time using reversible covalent kinase inhibitors
- (2015) J Michael Bradshaw et al. Nature Chemical Biology
- Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies
- (2015) BING XIA et al. Oncology Letters
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
- (2013) J. A. Woyach et al. BLOOD
- Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus
- (2012) Jack Hutcheson et al. ARTHRITIS RESEARCH & THERAPY
- Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas
- (2011) T. L. Naylor et al. CANCER RESEARCH
- Pathogenesis of Non-Hodgkin's Lymphoma
- (2011) Hendrik Nogai et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
- (2011) Betty Y Chang et al. ARTHRITIS RESEARCH & THERAPY
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells
- (2010) B. Kloo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started